Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rob P. Davis
Observed names:
Rob Davis,
Rob P Davis
Institution:
GlaxoSmithKline (United Kingdom)
Observed institutions:
GlaxoSmithKline (United Kingdom),
GlaxoSmithKline Research & Development Limited (United Kingdom)
OpenAlex ID:
A5019088409
Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation
2015
·
Huw D Lewis
, John Liddle
, et al.
·
Nature Chemical Biology
·
878
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins
2020
·
Robert J. Watson
, Paul Bamborough
, et al.
·
Journal of Medicinal Chemistry
·
103
Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor
2011
·
John Liddle
, Francis L. Atkinson
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
63
Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors
2021
·
Simon C. C. Lucas
, Stephen J. Atkinson
, et al.
·
Journal of Medicinal Chemistry
·
28
PDF
Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease
2018
·
Michael D. Barker
, John Liddle
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
26
Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate
2022
·
Philip G. Humphreys
, Stephen J. Atkinson
, et al.
·
Journal of Medicinal Chemistry
·
23
Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors
2016
·
Neil S. Garton
, Michael D. Barker
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
11
Show more works
View as search
Works count:
7
Citation count:
1,132
H-index:
7
I10-index:
7
Year
Topic
Type